The FDA has started a priority, six-month review of the marketing application, so Roche should get a decision on the application by October 23, barring any delays. Ranibizumab PDS is also under ...

Roche is to bolster its cancer pipeline with ... designation in Europe in October. Pfizer’s Xalkori is already approved to treat patients with ROS1 mutations (alongside its use in ALK+ patients ...

Roche has secured its third antibody-drug conjugate pact of the year, this time agreeing to hand $36 million in upfront payments to Oxford BioTherapeutics. The agreement will also see U.K.-based ...

Roche Diagnostics has promoted Johnny Smith to global head of communications. Smith started in the role March 1. He reports to Barbara Schädler, head of group communications for Roche, which comprises ...